GRAIL Inc.

2024 started with early optimism at a potential rebound in deal-making with many unpartnered life sciences assets in Phase III or later (and a lot more at earlier stages), more than $800bn available i

Rahul Rao, deputy director of Federal Trade Commission's Bureau of Competition, said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in t

The US Federal Trade Commission took on the biopharmaceutical industry last year with a series of unusual enforcement actions challenging proposed mergers and industry patent listings. Stakeholders ar

The US Federal Trade Commission took aim at the biopharma industry last year with a series of aggressive enforcement actions in the M&A arena. For the first time it challenged a pharma merger based on